Goldline Pharmaceutical Ipo
Goldline Pharmaceutical IPO Review & Key Points
Review: May Apply
IPO Lead Managers aka Merchant Bankers
Cumulative Capital Pvt. Ltd.
| Name of the Company | Face Value (₹) | EPS basic (₹) | EPS Diluted (₹) | RONW (%) | P/E Ratio | NAV (₹) |
| Powerica Limited | 5 | 15.26 | 15.26 | 15.37 % | 24.45 | 99.76 |
| Listed Peers | ||||||
| Cummins India Limited | 2 | 72.15 | 72.15 | 26.45% | 64.13 | 272.78 |
| Kirloskar Oil Engines Limited | 2 | 33.71 | 33.60 | 15.85% | 43.24 | 212.60 |
| NTPC Green Energy Limited | 10 | 0.67 | 0.67 | 2.58% | 129.40 | 21.88 |
| Acme Solar Holdings Limited | 2 | 4.55 | 4.53 | 5.59% | 50.74 | 74.54 |
| Adani Green Energy Limited | 10 | 8.37 | 8.37 | 11.90% | 101.53 | 76.62 |
| IPO Open Date | May 12, 2026 |
| IPO Close Date | May 14, 2026 |
| Face Value | ₹10 Per Equity Share |
| IPO Price Band | ₹41 to ₹43 Per Share |
| Issue Size | Approx ₹12 Crores |
| Fresh Issue | Approx ₹12 Crores |
| Issue Type | Book build Issue |
| IPO Listing | BSE SME |
| DRHP Draft Prospectus | |
| RHP Draft Prospectus |
| Application | Lot Size | Shares | Amount |
| Retail Minimum | 2 | 6,000 | ₹2,58,000 |
| Retail Maximum | 2 | 6,000 | ₹2,58,000 |
| S-HNI Minimum | 3 | 9,000 | ₹3,87,000 |
| S-HNI Maximum | 7 | 21,000 | ₹9,03,000 |
| B-HNI Minimum | 8 | 24,000 | ₹10,32,000 |
| Investor Category | Share Offered | Shares (%) |
| Anchor Investor | 7,32,000 Shares | 27.11% |
| QIB (Ex. Anchor) | 5,40,000 Shares | 20.00% |
| NII Shares Offered | 3,90,000 Shares | 14.44% |
| Retail Shares Offered | 9,00,000 Shares | 33.33% |
| Anchor Bidding Date | May 11, 2026 |
| Anchor Investors List | |
| Shares Offered | 7,32,000 Shares |
| Anchor Size | [.] Cr. |
| lock-in period end date 50% shares (30 Days) | 2026 |
| lock-in period end date 50% shares (90 Days) | 2026 |
| IPO Open Date: | May 12, 2026 |
| IPO Close Date: | May 14, 2026 |
| Basis of Allotment: | May 15, 2026 |
| Refunds: | May 18, 2026 |
| Credit to Demat Account: | May 18, 2026 |
| IPO Listing Date: | May 19, 2026 |
| IPO Bidding Cut-off Time: | May 14, 2026 – 5 PM |
| Particular | Shares | % Share |
| Promoter Holding Pre Issue | 69,00,000 | 79.70% |
| Promoter Holding Post Issue | 96,00,000 | -% |
| Purpose | Crores |
| Prepayment or repayment of all or a portion of certain outstanding borrowings availed by our company | ₹8.90 |
| General Corporate Purpose | ₹- |
| Period Ended | Revenue | Expense | PAT | Assets |
| 2023 | ₹19.85 | ₹19.45 | ₹0.26 | ₹19.39 |
| 2024 | ₹23.57 | ₹21.04 | ₹1.81 | ₹22.93 |
| 2025 | ₹28.06 | ₹24.20 | ₹2.83 | ₹26.28 |
| Dec 2025 | ₹21.41 | ₹18.40 | ₹2.22 | ₹27.40 |
| KPI | Values |
| ROE: | 35.84% |
| ROCE: | 38.46% |
| EBITDA Margin: | 20.79% |
| PAT Margin: | 10.10% |
| Debt to equity ratio: | 1.50 |
| Earning Per Share (EPS): | ₹4.10 (Basic) |
| Price/Earning P/E Ratio: | N/A |
| Return on Net Worth (RoNW): | 27.37% |
| Net Asset Value (NAV): | ₹12.38 |
| Company | EPS | PE Ratio | RoNW % | NAV | Income |
| Mono Pharmacare Limited | 1.75 | 7.57 | 9.90% | 17.66 | 168.34 Cr. |
| Chandra Bhagat Pharma Limited | 1.14 | 28.94 | 2.86% | 39.72 | 86.72 Cr. |
| Period Ended | Revenue | Expense | PAT | Assets |
| 2023 | ₹184.81 | ₹154.97 | ₹32.10 | ₹251.58 |
| 2024 | ₹206.45 | ₹175.85 | ₹34.44 | ₹339.25 |
| 2025 | ₹322.58 | ₹261.43 | ₹28.13 | ₹455.49 |
| Dec 2025 | ₹236.50 | ₹186.96 | ₹38.69 | ₹561.34 |